Ono Pharma to Present Positive Phase 2 Data for Tirabrutinib in PCNSL and ONO-4578 in Rectal Cancer at ASCO 2025
Ono Pharmaceutical will present positive results from the Phase 2 PROSPECT study of tirabrutinib for relapsed or refractory primary central nervous system lymphoma at ASCO 2025 in Chicago.
© Copyright 2025. All Rights Reserved by MedPath